Panacea Biotec Reports Zero Shares Dematerialized in July 2026
Panacea Biotec Limited reported no shares dematerialized in July 2026. As of July 31, 2026, total dematerialized shares were 6,11,05,526 (NSDL: 5,26,65,454; CDSL: 84,40,072). A certificate from the RTA confirms these figures.
This is a standard, routine disclosure regarding share dematerialization status. It does not involve any significant corporate actions, financial results, or strategic changes that would impact the company's stock or operations.
The announcement is a routine regulatory filing providing information on share dematerialization, with no significant positive or negative financial or operational news.
Panacea Biotec Limited has informed the stock exchanges regarding the dematerialization of shares during July 2026. As per the SEBI (Depositories and Participants) Regulations, 2018, the company stated that no shares were dematerialized in the past month.
The total number of shares dematerialized as of July 31, 2026, stood at 6,11,05,526. This includes 5,26,65,454 shares dematerialized through NSDL and 84,40,072 shares through CDSL.
A certificate from the company's Registrar and Share Transfer Agent (RTA), Skyline Financial Services Pvt. Ltd., confirming these dematerialization details as of July 31, 2026, has also been enclosed. The company has requested acknowledgment of receipt for this information.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.